Humulin N (Insulin Human (Rdna))

Humulin N is indicated for the long‑acting control of blood glucose in patients with diabetes. It is commonly employed in the following clinical situations:

• Basal insulin therapy for type 1 diabetes mellitus.
• Basal insulin therapy for type 2 diabetes mellitus.
• Combination with rapid‑acting insulin analogues for intensive insulin regimens.
• Use in adults, adolescents, and children when a stable, prolonged insulin effect is required.
• Adjunct to diet and exercise for overall glycaemic management.

• Humulin N provides exogenous human insulin that binds to insulin receptors on cell membranes, activating the intrinsic tyrosine kinase activity. This triggers downstream signaling pathways, including the PI3K‑Akt cascade, which promotes translocation of GLUT‑4 transporters to the cell surface, enhances glucose uptake in muscle and adipose tissue, and suppresses hepatic gluconeogenesis, thereby lowering plasma glucose concentrations.

Adverse reactions to Humulin N vary in frequency and severity.

Common

• Injection site redness, swelling, or bruising.
• Low blood glucose (hypoglycaemia) episodes.
• Weight gain.
• Lipodystrophy at injection sites.

Serious

• Severe hypoglycaemia with neuroglycopenic symptoms.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Persistent hypoglycaemia unresponsive to carbohydrate intake.
• Edema or heart failure exacerbation in susceptible patients.

When prescribing or using Humulin N, consider the following precautions:

• Assess renal and hepatic function, as impairment may alter insulin requirements.
• Monitor for signs of hypoglycaemia, especially in patients with irregular meals or increased physical activity.
• Use caution in pregnant or breastfeeding individuals; safety data are limited.
• Adjust doses when initiating or discontinuing concomitant medications that affect glucose metabolism.
• Educate patients on proper injection technique to reduce lipodystrophy risk.
• Review cardiovascular status, as fluid retention may worsen heart failure.

Humulin N may interact with several drug classes.

Avoid

• Concurrent use of other insulin products without dose adjustment, which can precipitate severe hypoglycaemia.
• Beta‑blockers that mask hypoglycaemia symptoms.

Use with caution

• Oral hypoglycaemic agents (e.g., sulfonylureas, meglitinides) that increase insulin secretion.
• Corticosteroids, which raise blood glucose and may require higher insulin doses.
• Diuretics, particularly thiazides, that can impair glucose tolerance.
• ACE inhibitors or ARBs, which may potentiate insulin’s glucose‑lowering effect.
• Alcohol, which can cause unpredictable glucose fluctuations.